Key facts today
Eli Lilly's weight-loss drug Zepbound now holds nearly 60% of the obesity market, outpacing Novo Nordisk's Wegovy, which had 281,725 weekly U.S. prescriptions in late July.
Eli Lilly faces a manageable near-term risk of about 4% on core profit due to U.S. tariffs and drug pricing reforms, according to a Morningstar report.
Cigna's Evernorth unit reports over 50% of clients cover weight management drugs like Eli Lilly's Zepbound, contrasting with only 15-20% of smaller employers offering similar coverage.
0.25 USD
9.41 B USD
40.01 B USD
About Eli Lilly and Company
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
ARDEUT111192
FIGI
BBG000HFVYP1
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Related stocks
Eli Lilly (LLY) Weekly Chart – Double Top Patterns & Major SuppoLLY has formed consecutive double top patterns within a broad descending channel.
Price recently tested a long-term major support zone and bounced strongly, signaling renewed buying interest. If this momentum holds, a move toward the major resistance near $973 is possible, aligning with the upper
$LLY: Decision Zone — Wedge Breakout or Retest of 685Eli Lilly (LLY) rebounded off the long-term trendline and weekly demand box (≈622–686) and is compressing inside a descending wedge.
Bullish path (blue): a clean break and retest of wedge resistance opens room toward the prior extension/marker near ~970.
Bearish path (red): rejection at the
Lilly Has Fallen. Can it Get Up?Eli Lilly has been trending lower, and some traders may see further downside risk in the pharma giant.
The first pattern on today’s chart is the bearish gap on August 7. The decline came despite better-than-expected quarterly results, which may reflect weakening fundamentals.
Second is the May 23
LLY - Clean Levels UpdatedEli Lilly's hit those 708.49 and 711 levels I mentioned in my previous LLY post.
I've added some weekly levels, and a couple relevant spots from my boxed LLY chart.
If LLY loses steam up here we could easily see a retest of that box top area in the $680 - $678 range. Otherwise if we see a market
LLY $720 Call Setup: Don’t Miss Out on This Breakout Play!🚀 LLY Weekly Options Analysis (2025-08-17) 🚀
### 🔎 Comprehensive Multi-Model Insights
**Grok/xAI Report**
* 📊 RSI: Neutral (Daily & Weekly \~46)
* 📈 Flow: Call/Put = **3.87 (Bullish bias)**
* 🔊 Volume: Weak vs. previous weeks → ⚠️ no strong institutional support
* 🛑 Trade: **No entry** (weak conf
LLY AUG-2025Eli Lilly ( NYSE:LLY ) rebounded strongly from the 640 support zone after institutional absorption. Price is now targeting the gap at 740, aligning with prior distribution levels. Sustained momentum above 700 could drive continuation into 737–740. Failure to hold above 640 risks a deeper move into t
Red Pill or Blue Pill?Red Pill first - let’s stick to some harsh realities, but using technical analysis only.
Why the harsh crash?
We were rejected at the Value Area high at $972, followed by another rejection at the 0.786 Fibonacci level at $916, along with the top of the flag pattern of this giant bull flag. This wa
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065Yield to maturity
—
Maturity date
Oct 15, 2065
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064Yield to maturity
—
Maturity date
Aug 14, 2064
LLY4492876
Eli Lilly and Company 3.1% 15-MAY-2027Yield to maturity
—
Maturity date
May 15, 2027
LLY6153506
Eli Lilly and Company 4.0% 15-OCT-2028Yield to maturity
—
Maturity date
Oct 15, 2028
LLY6153507
Eli Lilly and Company 4.25% 15-MAR-2031Yield to maturity
—
Maturity date
Mar 15, 2031
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063Yield to maturity
—
Maturity date
Feb 27, 2063
LLY4492882
Eli Lilly and Company 3.95% 15-MAY-2047Yield to maturity
—
Maturity date
May 15, 2047
LLY5750404
Eli Lilly and Company 4.5% 09-FEB-2029Yield to maturity
—
Maturity date
Feb 9, 2029
LLY5871807
Eli Lilly and Company 4.6% 14-AUG-2034Yield to maturity
—
Maturity date
Aug 14, 2034
LLY6153403
Eli Lilly and Company 4.9% 15-OCT-2035Yield to maturity
—
Maturity date
Oct 15, 2035
LLY6003479
Eli Lilly and Company 4.9% 12-FEB-2032Yield to maturity
—
Maturity date
Feb 12, 2032
See all LLYD bonds